Claudin18.2 Antibody-Drug Conjugate with Stable Linker
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for therapeutic strategies targeting Claudin18.2 with high affinity, specificity, and low immunogenicity, as well as antibody-drug conjugates (ADCs) that exhibit high activity, low toxicity, long half-life, and good specificity or affinity.
Innovation Solution
The development of an antibody-drug conjugate (ADC) specifically targeting Claudin18.2, which binds with high affinity to cells expressing this protein, enters cells through endocytosis, and exhibits a bystander killing effect, high anti-tumor efficacy, low toxicity, and good stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If naked monoclonal antibodies targeting cell surface tumor antigens are used, then the therapy is simple to administer, but the anti-tumor efficacy is insufficient
Solution Approach 1:
The patent combines a monoclonal antibody with a cytotoxic drug molecule to create an antibody-drug conjugate (ADC). The antibody portion provides target specificity and ease of administration, while the cytotoxic drug portion provides potent anti-tumor activity. This merging resolves the contradiction by maintaining the administrative simplicity of antibodies while adding the efficacy of cytotoxic agents.
Solution Approach 2:
The ADC is a composite therapeutic agent consisting of three distinct components: the antibody (HB37A6), a linker, and a cytotoxic drug (auristatin derivative). This composite structure allows each component to contribute its unique properties - the antibody for targeting, the linker for stable connection, and the drug for cell killing - thereby achieving both ease of administration and high efficacy.
2Reliability
If ADCs with high cytotoxic activity are developed, then the anti-tumor effect is enhanced, but the toxicity increases
Solution Approach 1:
The patent uses a specially designed linker as an intermediary between the antibody and the cytotoxic drug. This linker maintains the drug in a stable, non-toxic state during circulation while enabling controlled release of the cytotoxic agent inside target cells. This resolves the toxicity contradiction by mediating the delivery of high-potency drugs only to intended targets.
Solution Approach 2:
The ADC exhibits local quality by concentrating cytotoxic activity specifically at the tumor site through antibody-mediated targeting. The high cytotoxic effect is localized to CLDN18.2-expressing cells, while normal tissues receive minimal exposure to the toxic drug, thereby achieving high anti-tumor effect with reduced systemic toxicity.
3Reliability
If the ADC enters cells through endocytosis to kill target cells, then the specificity is improved, but the mechanism complexity increases
Solution Approach 1:
The ADC utilizes the cell's own endocytic machinery to enter target cells. The antibody portion of the ADC binds to CLDN18.2 on the cell surface, and the cell's natural endocytic pathways automatically internalize the conjugate. This self-service approach improves specificity for CLDN18.2-positive cells while avoiding the need for complex external delivery systems.
4Duration of action of moving object
If the ADC has long half-life for sustained therapy, then the dosing frequency is reduced, but the accumulation of toxic metabolites may increase
Solution Approach 1:
The patent employs parameter changes in the linker design to control the stability and degradation kinetics of the ADC. The linker is engineered to maintain stability during circulation (providing long half-life) while enabling controlled degradation inside target cells to release the cytotoxic drug. This resolves the half-life contradiction by changing the stability parameter in different biological compartments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ADC demonstrates remarkable efficacy in killing target cells, including those with moderate and high expression levels of Claudin18.2, while maintaining low toxicity and stability, thereby providing a potent therapeutic option for cancers such as gastric and pancreatic cancer.
Implementation Method 1
capable of entering cells through endocytosis to kill target cells
Data Source
AI summary
The present invention relates to an antibody-drug conjugate (ADC) targeting Claudin18.2 and a composition containing the molecule. The present invention further relates to therapeutic and diagnostic uses of the antibodies and antibody fragments.